Last reviewed · How we verify
CYP2C19 Genotype Guided DAPT
This is a pharmacogenomic-guided dual antiplatelet therapy (DAPT) strategy that uses CYP2C19 genotyping to optimize antiplatelet drug selection and dosing for improved cardiovascular outcomes.
This is a pharmacogenomic-guided dual antiplatelet therapy (DAPT) strategy that uses CYP2C19 genotyping to optimize antiplatelet drug selection and dosing for improved cardiovascular outcomes. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement, Secondary prevention of stent thrombosis and recurrent cardiovascular events in CYP2C19 genotype-guided patient populations.
At a glance
| Generic name | CYP2C19 Genotype Guided DAPT |
|---|---|
| Also known as | Guided DAPT |
| Sponsor | Zunyi Medical College |
| Drug class | Pharmacogenomic-guided antiplatelet therapy strategy |
| Target | CYP2C19 enzyme; P2Y12 receptor (indirect) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
CYP2C19 is a cytochrome P450 enzyme critical for the metabolism of clopidogrel (Plavix), a commonly used antiplatelet agent. Patients with CYP2C19 loss-of-function variants have reduced conversion of clopidogrel to its active form, leading to diminished antiplatelet effects and increased risk of stent thrombosis or recurrent cardiovascular events. Genotype-guided DAPT uses CYP2C19 testing to identify poor metabolizers and either increase clopidogrel dose, switch to alternative P2Y12 inhibitors (prasugrel or ticagrelor) with less CYP2C19 dependence, or adjust therapy accordingly to optimize antiplatelet efficacy.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement
- Secondary prevention of stent thrombosis and recurrent cardiovascular events in CYP2C19 genotype-guided patient populations
Common side effects
- Bleeding (major and minor)
- Stent thrombosis
- Recurrent myocardial infarction
Key clinical trials
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR (PHASE4)
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing (NA)
- CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention (PHASE4)
- Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction (PHASE4)
- Clopidogrel Monotherapy in Patients With High Bleeding Risk (PHASE4)
- Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYP2C19 Genotype Guided DAPT CI brief — competitive landscape report
- CYP2C19 Genotype Guided DAPT updates RSS · CI watch RSS
- Zunyi Medical College portfolio CI